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Experimental animal models of tuberculosis (TB) have convincingly demonstrated that
inhaled dose predicts immunopathology and survival. In contrast, the importance of
inhaled dose has generally not been appreciated in TB epidemiology, clinical science, or
the practice of TB control. Infectiousness of TB patients has traditionally been assessed
using microscopy for acid-fast bacilli in the sputum, which should be considered only
a risk factor. We have recently demonstrated that cough aerosol cultures from index
cases with pulmonary TB are the best predictors of new infection among household
contacts. We suggest that cough aerosols of M. tuberculosis are the best surrogates
of inhaled dose, and we hypothesize that the quantity of cough aerosols is associated
with TB infection versus disease. Although several factors affect the quality of infectious
aerosols, we propose that the particle size distribution of cough aerosols is an important
predictor of primary upper airway disease and cervical lymphadenitis and of immune
responses in exposed hosts. We hypothesize that large droplet aerosols (>5μ) containing
M. tuberculosis deposit in the upper airway and can induce immune responses without
establishing infection. We suggest that this may partially explain the large proportion
of humans who never develop TB disease in spite of having immunological evidence
of M. tuberculosis infection (e.g., positive tuberculin skin test or interferon gamma
release assay). If these hypotheses are proven true, they would alter the current
paradigm of latent TB infection and reactivation, further demonstrating the need for
better biomarkers or methods of assessing TB infection and the risk of developing
disease.
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Introduction
In spite of the devastating impact of tuberculosis (TB) on mankind throughout history, scientists
have struggled to decipher the determinants of the wide spectrum of infection and disease in TB.
Data from over 50 years ago have suggested that the vast majority (90%) of persons infected with
the causative agent, Mycobacterium tuberculosis, never manifest any symptoms or signs of disease.
These persons are diagnosed with latent TB infection (LTBI) only by an immunological signature
of infection using the traditional tuberculin skin test (TST) or a more modern interferon gamma
release assay (IGRA) of the blood. It is estimated that one-third of the global population, or 2
billion people, are latently infected with TB. At the opposite end of the spectrum are persons
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who die of respiratory failure due to destruction of their lungs or
whopresentwithTB sepsis due to dissemination ofM. tuberculosis
in their bloodstream and to other organs. The variable balance
between the immune response and virulence of the bacilli is
responsible for the containment ofM. tuberculosis in LTBI, for the
destruction of lungs and other tissues due to an overly aggressive
response, and for disseminated disease due to loss of control of
M. tuberculosis. The actions of the immune system responsible
for this variability are highly complex and are addressed by other
authors in this issue. However, we present a simple concept that
is poorly appreciated in both research and control of human TB:
a major determinant of immunopathology in TB is the inhaled
dose of M. tuberculosis. Our primary hypothesis is that small
inhaled doses are more likely to result in LTBI, and that large
inhaled doses are more likely to result in primary TB disease. In
other words, we hypothesize that the quantity of inhaled dose
predicts the immunopathology following infection. We propose
that cough aerosol cultures ofM. tuberculosis fromhumanpatients
with active TB cases are better surrogates of inhaled dose than
are sputa smears for acid-fast bacilli (AFB) or sputa cultures of
M. tuberculosis.
We also propose that the quality of the infectious aerosol is
an important determinant of immunopathology. The quality of
an infectious aerosol includes its particle size distribution, viru-
lence and infectivity of the pathogen, the duration of exposure to
antimycobacterial drugs, desiccation, ultraviolet light, and other
stressors. We will focus our discussion on the particle size dis-
tribution. We hypothesize that when M. tuberculosis is present
in large droplet aerosols it deposits in the upper airways and
produces immune responses but not necessarily infection. This
would explain a large number of persons who are currently diag-
nosed as having LTBI but who never develop active TB disease.
This idea also addresses the fundamental question of whether
all those with positive TSTs or IGRAs are infected with viable
M. tuberculosis (1). These hypotheses are based on our recent
data on cough aerosols of M. tuberculosis; a new synthesis and
interpretation of the literature on TB epidemiology, pathogenesis
and clinical presentations; and principles of aerosol science. These
concepts challenge current dogma in our understanding of TB,
but we respectfully suggest that they help explain uncertainties in
the science of TB and that they can be readily tested in the near
future. If proven true, they would change the current paradigm
of LTBI diagnosis and treatment. They would also emphasize the
need for better biomarkers to confirm the presence of live bacilli
within the human host and to predict the risk of reactivation
of LTBI.
Hypothesis 1. The magnitude of cough aerosol cultures in
fine (5μ) aerosols of M. tuberculosis from index cases
of pulmonary TB is positively associated with TB disease
(Figure 1).
(a) Large magnitudes of cough aerosol cultures are associated
with primary TB.
(b) Small magnitudes of cough aerosol cultures are associated
with reactivation TB within the first few years of exposure.
FIGURE 1 | Schematic of Hypothesis 1 demonstrating the proposed
concept that larger inhaled doses are more likely to produce primary
TB disease (A) and lower doses are more likely to produce latent TB
infection (B).
Inhaled Dose–Response in Animal Models
of TB
General Principle of the Inoculum Effect
A general principle in the study of infectious diseases is that
the size of the inoculum, or dose, and virulence of a given
pathogen predict the establishment of infection and subsequent
pathogenesis in the host (2). This principle has been demonstrated
in bacteria (3–5), fungi (6, 7), viruses (8–10), and parasites (11).
For example, classic experiments in which human volunteers
ingested typhoid bacilli demonstrated the relationship between
dose and the pathogenesis of typhoid fever (12, 13). However,
such studies cannot ethically be done to understand the effect of
inhaled dose and TB pathogenesis in humans. Our understanding
of the effects of inhaled dose on the pathogenesis of TB is based
largely on experimental work.
Brief Review of the History of the Science of
Transmission of M. tuberculosis
Robert Koch conclusively demonstrated thatM. tuberculosis is the
etiologic agent of TB in 1882, but it was not until 1959 that Richard
Riley and William Firth Wells and colleagues first demonstrated
airborne transmission ofM. tuberculosis to guinea pigs exposed to
the air from humans with pulmonary TB in an experimental TB
ward. Since then, TB has been considered the prototype disease
of airborne transmission with a general acceptance that the other
modes of transmission, i.e., large droplet and contact, do not
occur. However, this is not absolute as there are reports indicating
that the other modes of transmission rarely occur. Children can
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develop cutaneous TB in the form of chancres or warty TB from
direct inoculation of bacilli onto damaged skin (14). A rare case
of contact transmission occurred when a physician performed
mouth-to-mouth resuscitation on a TB patient and acquired pri-
mary cutaneous TB in the nasolabial area (15). Also, direct injec-
tion of M. tuberculosis among pathologists and other laboratory
workers can produce “prosectors warts,” i.e., granulomas at the
site of accidental injection, first described by Laennec regarding
a lesion on his own finger (16). Under our second hypothesis
section later in this paper, we review the evidence for upper airway
deposition ofM. tuberculosis by large droplet aerosols.
Koch was also the first to demonstrate a dose–response effect
of infection on pathogenesis (17). His observation of the asso-
ciation of higher mortality with increasing inoculum size was
later confirmed by Glover (18) and Youmans (19). Glover’s
semi-quantitative estimate of inhaled dose was also associated
with lung pathology findings, ranging from small granulomatous
lesions in themice exposed to the lowest doses ofM. bovis to gross
suppurative consolidation in those exposed to the highest doses of
M. bovis (Figure 2).
Experimental aerogenic infections of the mouse, guinea pig,
and rabbit models (20, 21) have demonstrated similarities in
the kinetics of immunopathogenesis after infection. After infec-
tion in a given host that is not highly susceptible, growth
occurs in the lung at a logarithmic rate for the first 2–3weeks,
and then plateaus at approximately 4weeks when the infec-
tion is controlled by acquired immunity. In an immunologi-
cally naïve animal, more extensive replication of the bacteria
is needed to induce the immune response, so the time course
may be longer (approximately 3–4weeks) than in the animal
with pre-existing immunity (21). The genetic susceptibility of
the animal determines the immune response to a given bacil-
lary strain. For example, in Lurie’s studies of rabbits of vary-
ing susceptibility to infection, one resistant strain produced
one grossly visible pulmonary tubercle per 600 viable H37Rv
bacilli inhaled, whereas a susceptible strain developed one tuber-
cle per 107 bacilli (20). However, for a given strain of host
rabbit and a given strain of tubercle bacillus, intensity of air-
borne dose was associated with an increased number or rab-
bits infected and with shorter survival time. Similarly, natu-
ral resistance to TB in the rabbit model can be overcome by
larger inhaled doses of tubercle bacilli (22), suggesting a strong
FIGURE 2 | Increasing mortality and pathological changes in mice with
increasing inhaled doses of Mycobacterium bovis. Data from Ref. (18).
dose-response relationship between inoculum size and risk of
disease.
More recent studies using the same strain of mouse (C57BL/6)
exposed to aerosols of three different strains of M. tuberculosis
demonstrated that there was more rapid progression of disease
associated with increasing bacillary concentrations in the aerosol
within each strain, although a similar rapid progression of disease
was observed when comparing more to less virulent strains. In
other words, high inhaled doses of less virulent strains may pro-
duce similar lung pathology as lower doses of less virulent strains
(23). In addition to the course of TB disease, the inhaled inoculum
size has recently been shown to influence the therapeutic response
to antituberculous medications (24).
These animal models all reflect acute infection, or what in
humans is termed “primary TB disease” or “progressive primary
disease.” This occurs most commonly in children <5 years of age
(25) or in HIV infected persons (26). However, in one large study
of 20,687 household contacts (HHCs) age 5 years or older), 598
(4.9%) had primary TB (25).
Models of LTBI
LTBI has been difficult to study due to the lack of good animal
models until recently. The “Cornell Model” of LTBI involved
the establishment of active TB disease that was then partially
treated with antituberculous agents (27). The mice were then
immunosuppressed to reactive TB disease in an effort to model
the reactivation of TB in humans. Although some humans do
reactivate LTBI due to immunosuppression, the vast majority of
humans reactivate spontaneously without the medical interven-
tion of immunosuppressive drugs. Why the majority of humans
have LTBI but never reactivate has never been explained.
Non-human primate models
Although the experimental mouse model has provided valuable
contributions to our understanding of the immunology of TB,
it does not sufficiently model key aspects of human TB disease,
notably necrotic lesions or cavitation or LTBI. Also, whereas the
guinea pig and rabbit models have pathology more similar to
humans, there are few immunologic reagents for these models.
Some of themost exciting data from animalmodels in recent years
has been generated using non-human primates (NHP) because
of the similarity of TB disease to human disease and because
of cross-reactivity of immunologic and molecular reagents with
humans.
Early experiments used intratracheal administration of M.
tuberculosis to Philippine cynomolgus monkeys (Macaca fascic-
ularis) (28). Delivery of very high doses of 104 or 105 colony-
forming units (CFU) of M. tuberculosis resulted in acute and
rapidly progressive and fatal multilobar pneumonia. However,
lower doses (<103 CFU) produced a more chronic and slowly
progressive form of pulmonary TB that was similar to human
disease sometimes with dissemination to other organs. Even lower
doses (101 or 102 CFU) resulted in some monkeys containing the
infection in a subclinical state.
Another group of investigators has used bronchoscopic admin-
istration of M. tuberculosis suspensions to infect 17 cynomolgus
macaques with a low dose of approximately 25CFU (29). They
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observed a range of pathology, with 7 classified as LTBI and
eight remained alive and well, without evidence of disease after
15–21months of observation. The other animals exhibited a range
of pathology similar to primary human TB, and one animal may
have reactivated with a small cavitary lesion.
Natural human infectionwithM. tuberculosismost often occurs
after inhalation of infectious aerosols and yet another group of
investigators have demonstrated that macaques infected by the
head-only aerosol route develop disease that appears to be very
similar to human TB. High doses of aerosols of M. tuberculosis
produce a fulminant fatal pneumonic TB in rhesus macaques
(30, 31). Lower doses of about 500CFU of CDC 1551 strain
produced asymptomatic, latent infections in 12 animals except
for one with signs of active TB over 9weeks of observation (32).
All 11 appearing to have LTBI had no evidence of M. tuber-
culosis on bronchoalveolar lavage (BAL) at 9 weeks. Six animals
were infected intravenously with simian immunodeficiency virus
(SIV), and they all developed culture-positive BALs, and some
had evidence of dissemination with positive blood cultures. The
resurgence of theNHPmodel of TB is in part due to the availability
of immunologic reagents for the study of AIDS, and reactivation
of TB infection produced by either bronchoscopic instillation
or by aerosol exposures, and has been demonstrated due to co-
infection of macaques with SIV (32, 33). The NHP model has
also demonstrated reactivation of LTBI with inhibition of tumor
necrosis factor (TNF) alpha similar to that in humans (34).
In summary, the NHP model of TB has demonstrated the
importance of inhaled (or instilled) dose in the establishment of
LTBI versus primary (progressive) TB disease. What is not known
is whether dose is a predictor of which patients with LTBI will
reactivate in the future. We propose the concept that exposure
of humans to large concentrations of infectious aerosol results in
both (1) an increased risk of inhalation of live bacilli that can
establish a focus of infection and (2) increased opportunities for
multiple episodes of inhalation of one or more bacilli that may
establish multiple foci of infection. Given recent evidence about
the dynamic nature of the establishment of infection in a NHP
model (35), this would increase the chances that one of those
foci would result in a progressive infection acutely, as well as
reactivation of a focus of infection at a later time point.
Epidemiological Evidence Supporting a
Dose–Response Relationship
Epidemiologic studies have also suggested a dose–response rela-
tionship in TB immunopathogenesis. Epidemiologic studies of TB
have been hampered by the inability to measure inhaled dose, or
at least a measure of source strength from the index case with
TB. This resulted in the use of the sputum smear as an indirect
measure of bacillary load in the infectious aerosols generated by
TB patients.
Household Contact Studies
Our understanding of transmission of M. tuberculosis to humans
has been largely determined by epidemiological studies of HHCs
of patients with pulmonary TB and by reports of nosocomial
outbreaks. Close contacts of persons with sputum-smear-positive
TB have the highest prevalence of LTBI compared to other pop-
ulations, and they are second only to HIV infection for the
highest risk of progressing from LTBI to active disease (36, 37).
Increased transmission has been consistently associated with spu-
tum smear-positive cases compared to that of sputum smear-
negative cases. This has been most well-documented by compar-
ing TSTs in HHCs who are exposed to patients with sputa that
is smear-positive for AFB versus those with sputa that is smear-
negative for AFB but culture-positive for M. tuberculosis. For
example, in a classic study done in Canada, there was a gradient
of higher rates of infection and secondary TB disease cases among
HHCs exposed to sputum smear-positive cases, HHCs compared
to smear-negative cases, and community controls (38). Among
close contacts who developed active TB, 92% were exposed to
a smear-positive case and only 8% to a smear-negative case. In
another large study done in Chennai, India, the 15-year risk
of progression to disease was highest among HHCs of sputum
smear-positive/culture-positive cases (adjusted RR= 3.4; 95% CI
3.0–3.9) compared to contacts of sputum smear-negative/culture-
positive cases (aRR 1.7; 1.4–2.0) and community controls without
household exposure to TB (39). In a more recent study conducted
in Galicia, Spain during 1996–2011 (40, 41), there were 3822 cases
of smear-negative TB, most of them identified in contact tracing.
The frequency of LTBI in HHC of these patients was similar to
contacts of smear-positive cases (30.1 versus 33.4%). By contrast,
the frequency of TB disease in HHC of smear-negative cases was
<20% that of smear-positive cases.
The observed effect of AFB smear-positivity is most likely a
simple quantitative difference in the concentration of bacilli in the
respiratory secretions of the source cases, as approximately 5,000–
10,000 bacilli per milliliter must be present for detection by direct
microscopy with Ziehl–Neelsen staining (42).
The percentage of TST-positive contacts of sputum smear-
positive cases has varied from 1.1 to 73%, and that of contacts of
smear-negative cases has ranged from 0 to 46%, with community
rates from <1 to 41%. In a community-based study in England
between 1948 and 52, positive TSTs were found in 65.2% of
children exposed to a smear-positive case and 26.8% exposed to
a smear-negative case (43). A strength of this study was that cases
of active TB disease were also tracked. Positive TSTs were found
in 14.4% of children exposed to a smear-positive case and in 3%
of children exposed to a smear-negative case. However, interpre-
tation of these data must include the background or community
prevalence of a positive TST, and these data may vary widely (44).
Although the TST has been a useful tool, it has many limitations,
not the least of which is the inability to detect when infection
occurred (44, 45).
Furthermore, epidemiological data suggest that there ismarked
variability of transmission from sputum-based studies (46). For
example, in a Dutch study of contacts to smear-positive index TB
cases in five clinics in Rotterdam from 1967 to 69, only 22 of 80
(27.5%) index cases were found to have infected their contacts.
However, when the distributionwas stratified by age, 57% of index
cases under 40 years of age infected their contacts but only 9% of
the index cases over 60 did so (47). Our preliminary data from
Florida also suggest that <30% of sputum smear-positive index
cases transmit to HHCs (see below), consistent with these data.
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Moreover, approximately 15% of transmission in three differ-
ent populations has been associated with sputum smear-negative
disease (46).
Intensity of Exposure and TB Outcomes
Intensity of exposure can be considered a surrogate measure of
inhaled dose due to the likelihood of larger and more frequent
exposures to infectious aerosols. Probably the best data regarding
the effect of intensity of exposure to M. tuberculosis on TB infec-
tion anddiseasewere theBritish Prophit Study conducted between
1933 and 1944, a time when TB was highly prevalent in the UK
(48). As the data in Figure 3 demonstrate, 80% of the nurses in
the highest exposure group demonstrated conversions of their
TSTs compared to 26% in community controls. The nurse cohorts
were more similar to each other and, therefore, more comparable
than the community controls and medical student. Compared to
nurses working in low exposure settings, those working with TB
patients in high exposure settings had a 48% increased risk of TST
conversion and a 41% increased risk of active TB.
Proximity of Exposure and TB Outcomes
Proximity can also be considered a surrogate for dose, as concen-
trations of airborne hazards are higher the closer a person is to an
infectious source. The association of proximity of exposure and
TB infection has been demonstrated in various settings. HHCs
sharing the same bed are at higher risk of infection than those
living in another room in the same residence (49–51). Patients
exposed to the infectious aerosols generated by a forceful irri-
gation of a tuberculous abscess were found to be infected along
a clear spatial gradient, with more patients infected with TB the
closer their rooms were along the hospital hallway (52). Similarly,
airline passengers on a transoceanic flight were more likely to
have evidence of TB infection the closer they were sitting to an
infectious TB patient (53). In a classic outbreak of TB aboard aU.S.
Navy ship, proximity and duration of contact were associated with
both TB infection and disease (54, 55). In an unusual exposure to
aerosols generated by water jet irrigation of a tuberculous abscess,
FIGURE 3 | Increasing rates of latent TB infection and active TB
among health care workers with increasing degrees of estimated
exposure to airborne M. tuberculosis. Data from Ref. (48).
there was a clear gradient of infection associated with proximity
(52). A limitation of the epidemiological data on proximity of
exposure is that it is not possible to determine if there were sim-
ply more frequent opportunities to become infected with similar
inhaled doses or if there were greater chances of being exposed
to larger concentrations of M. tuberculosis aerosols. Without a
better surrogate measure for inhaled dose, such questions cannot
be answered.
Transmission of M. tuberculosis and Cough
In addition to the bacillary load in the sputum, another known
risk factor for transmission is the frequency of cough. In Oslo
from 1940 to 53, the presence of cough in TB patients with smear-
positive sputa increased the risk of infections in exposed children
<5 years old (19.7 versus 5.5% in those without cough) (56). IN
another study, Loudon recorded 8-h overnight cough frequency
in newly admitted TB patients. Positive TSTs were found in 44%
of contacts of patients who had more than 48 coughs per 8 h
period compared to 28% of contacts of patients who had <12
coughs per night (57). In a more recent study in Brazil, we found
that cough assessed by a visual analog scale or the Leicester
CoughQuestionnairewas associatedwithmore transmission (58).
Epidemiological studies have found that more secondary cases
of TB are associated with men than with women, and that they
decrease with advancing age (59). One explanation for this finding
is that young patients tend to have more close contacts and more
contacts in general than do older patients. However, we suggest
that another explanation may be that younger persons and men
may have higher forced expiratory volumes and thus be able to
generatemore cough aerosols, aswe observed amongpatientswith
cystic fibrosis (CF) (60). Our preliminary data discussed below
support the importance of cough in generating infectious aerosols
ofM. tuberculosis.
Cough Aerosol Cultures as a Surrogate for
Inhaled Dose
While the inhaled dose can be manipulated in experimental ani-
mal models or in vitro systems, it is not possible to measure in
human infections. It is obviously unethical to deliberately expose
humans to varying concentrations of infectious aerosols of M.
tuberculosis, as has been done with less virulent diseases. So any
attempts to estimate inhaled dose must be observational and
retrospective in nature, as human patients present either after they
have become ill with active TB or after they have become exposed
to someone with active TB. Thus, we must use markers that are
surrogates for the inhaled dose.
Measurement of M. tuberculosis in
Cough-Generated Aerosols
Although aerosol transmission of TBwas convincingly established
over 50 years ago, microscopy of sputum smears for AFB contin-
ues to be used as the best laboratory test of infectiousness due
to the lack of better options. As discussed, whereas the sputum
AFB smear has been a useful surrogate marker of inhaled dose
for over 100 years, it clearly has its limitations and should only be
considered a risk factor for infectiousness (61, 62). There is a need
and capacity for a better surrogate marker of infectiousness.
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During the resurgence of TB in the U.S. in the late 1980s and
early 1990s, significant morbidity and mortality among health
care workers (HCWs) was recognized. The use of personal res-
piratory protection (PRP, e.g., N95 respirators) was especially
controversial, and the efficacy of PRP depends upon the particle
size distribution of the inhalation hazard, in this case that of
infectious aerosols containing M. tuberculosis. In addition, the
size distribution of infectious aerosols determines how long they
will remain airborne and where in the respiratory tract they
are most likely to deposit. Although Wells had estimated the
size range of infectious droplet nuclei to be 1–5 microns based
on experimental nebulization in the laboratory and theoretical
principles, the size of infectious aerosols of M. tuberculosis had
never been directly measured. To address this need, we developed
a “cough aerosol sampling system (CASS)” and initially aimed
to study cough aerosols from patients with TB to determine the
magnitude and particle size distribution of infectious aerosols of
M. tuberculosis to improve the scientific basis for interventions to
protect HCWs.
In our initial feasibility study using CASS in 16 AFB-positive
patients at a referral hospital in the U.S., we collected culturable
aerosols from only 4 (25%) of them (63). Aside from the small
sample size and preliminary nature of that work, one criticism
was that the sampling was done too close in proximity to the
patient, and thus may not represent what infects human patients
(64). However, this is probably not the case, as airborne droplets
desiccate to the size of infectious droplet nuclei in <1 s (65,
66). Others more informally suggested that the method was too
highly technical to be done in high incidence settings such as
sub-Saharan Africa. We subsequently used the CASS to collect
cough aerosols from sputum AFB-smear-positive TB patients in
Kampala, Uganda (67). We cultured M. tuberculosis from the
cough aerosols of 28 of 101 (27.7%; 95% confidence interval
[CI], 19.9–37.1%) patients with culture-confirmed TB, with a
median 16CFU (range, 1–701) in 10min of coughing. Nearly
all (96.4%) cultivable particles were 0.65–4.7μ in size, in agree-
ment with Wells’ theoretical predictions decades earlier. Posi-
tive aerosol cultures were associated with higher physical perfor-
mance (Karnofsky) scores (P< 0.016), higher sputum AFB smear
microscopy grades (P< 0.007), lower days to positive in liquid
culture (P< 0.004), stronger cough (P< 0.016), and fewer days
on TB treatment prior to aerosol collection (P< 0.047). In mul-
tivariable analyses, cough aerosol cultures were associated with
a salivary/mucosalivary (compared with purulent/mucopurulent)
appearance of sputum (odds ratio, 4.42; 95% CI, 1.23–21.43)
and low days to positive in liquid culture (per 1 day decrease;
odds ratio, 1.17; 95%CI, 1.07–1.33). This study demonstrated the
feasibility of using this research method in a resource-limited
setting and again suggested considerable variability in the ability
to produce infectious aerosols among TB patients. These data
suggest that although the bacillary load in sputum is one of the
predictors of cough aerosol cultures, sputum bacillary load is not
the only predictor. As noted by CDC investigators 30 years ago,
the bacillary load in the sputum should be considered a risk factor
for transmission, not the sole definition of infectiousness (62).
We followed up this study with another at the same site, this
time linking cough aerosol cultures from the index TB cases to
new infections among their HHCs, the primary outcome being
TST conversion (68). We enrolled 96 sputum culture-positive
index TB cases and their 442 contacts. Contacts of patients
with TB who produced high aerosols (>10CFU) were more
likely to have a new infection compared with contacts from low-
aerosol (1–9CFU) and aerosol-negative cases (83%, 32%, and
30%, respectively; P< 0.009). A high-aerosol patient with TB
was the only predictor of new M. tuberculosis infection in unad-
justed (odds ratio, 6.90; 95% confidence interval, 6.90, 16.42)
and adjusted analyses (odds ratio, 4.81; 95% confidence interval,
1.20–19.23). In other words, when cough aerosols were included
inmodels, the traditional indicators of infectiousness such as AFB
sputum smear, culture, or cavitation were no longer significant
(Figure 4).
In addition to these data, the use of cough aerosols as the
best indicator of infectiousness is supported by Hill’s guidelines
to strengthen the inference that a statistical association is also
causal (69). There is clearly more biological plausibility favoring
cough aerosols over sputum, as we know that pulmonary TB is not
transmitted by sputum but rather through aerosols, i.e., infectious
particles in the air. The experimental animal model evidence
reviewed above favors cough aerosols over sputum, although a
head-to-head comparison of the AFB sputum smear and cough
aerosol cultures has not been done. However, this can be tested
relatively easily using the approach of natural infection of guinea
pigs (64). Temporality is a difficult criterion to satisfy for any
surrogate, including sputum, necessarily obtained after infection
has occurred. The strength of the association now favors cough
aerosols given the data presented above, although it would be
ideal for those data to be replicated in other settings by other
investigators. Thus, there has not yet been enough data generated
to evaluate consistency. Finally, we have argued above that there
is a gradient, or dose–response, so we suggest that cough aerosols
are the best surrogate for inhaled dose.
Why shouldM. tuberculosis be one of the few pathogens which
is transmitted exclusively by the airborne route? We suggest that
one reason is that airborne transmission of other pathogens has
not been well studied. There is a growing body of literature
indicating that influenza is probably at least partially transmitted
by the airborne route as well as by large aerosols and direct
contact (70). Pseudomonas aeruginosa and other Gram-negative
bacilli (GNB) have been thought to be transmitted only by large
droplet transmission, but coughing CF patients readily produce
viable aerosols of these opportunistic pathogens (60, 71). How-
ever, transmission of disease via the fine aerosols of these GNBhas
not yet been demonstrated. It is most likely that many pathogens
can be aerosolized from the human respiratory tract by coughing
or sneezing. Whether or not transmission occurs is dependent on
the concentration at the time of emission from the index case and
subsequent dilution before inhalation by the exposed host as well
as survival of the immediate desiccation and temperature change,
exposure to ultraviolet light, and other environmental stresses
during transport (72).
Hypothesis 2. Large droplet aerosols (>5μ) of M. tuberculosis
that deposit in the upper airway can induce immune responses
without establishment of infection (Figure 5).
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FIGURE 4 | Increasing rates of infection among household contacts of
active cases of TB who produced larger cough aerosols (A). Increasing
amounts of interferon gamma output in an interferon-gamma release assay
among household contacts exposed to active cases of TB who produce larger
cough aerosols (B) [from Ref. (68); please see that paper for details regarding
numbers of subjects listed].
Although the discovery that TB is transmitted by the airborne
route was brilliant, we respectfully suggest that the assumption
that it is transmitted only by the airborne route is illogical. In this
section, we argue that although TB disease is clearly preferentially
transmitted by the airborne route, this is not exclusive or obligate.
Furthermore, sensitization or immunization may occur due to
deposition and presentation of tuberculous antigens in the upper
airway, without causing persistent infection or disease.
A Short History of the Science of TB
Transmission Mechanisms
Cornet (a student of Robert Koch) inoculated guinea pigs with
bacilli from the dust from the rooms of TB patients and was
able to produce infection in 40 of 118 samples in one experiment
and in 15 of 21 samples from medical wards, demonstrating that
tubercle bacilli can remain infectious for long periods of time.
The fact that M. tuberculosis can be found in dust attests to the
fact that large droplets from patients settle to the ground. Flugge
doubted the role of dust and appears to be the first to consider
cough aerosols as a primarymechanism of transmission of TB. He
sprayed dried versusmoist sputum of TB patients to create aerosol
exposures of guinea pigs and it was only those exposed to the
moist sprays that became infected, and he had patients cough into
the air, exposing guinea pigs. On finding that droplets on settle
plates between the patients and the guinea pigs grew M. tuber-
culosis, he concluded (we now know incorrectly) that these large
droplets caused TB (73). However, these early experiments indi-
cated that large droplet aerosols fromTB patients contained viable
M. tuberculosis.
Another early line of evidence indicating large droplet trans-
mission was the observation that M. tuberculosis could be culti-
vated from the nasal cavities of 9 out of 29 healthy hospital workers
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FIGURE 5 | Schematic of Hypothesis 2 demonstrating immunization
via the mucosa of the upper airway without the establishment of true
TB infection in the alveolar region of the lung.
with no evidence of TB disease (74). This is similar to another
potentially lethal respiratory infection, inhalation anthrax, that
was historically an occupational disease associated with exposures
towools and othermaterials contaminatedwithBacillus anthracis.
It was common to find anthrax spores in anterior nasal swabs
and pharyngeal washings in exposed workers who had no clinical
symptoms or signs of disease (75).
High Rates of Reactivation of LTBI
An accepted paradigm in the science of TB is that only 10% of
persons infected withM. tuberculosiswill develop TB disease, half
of those developing disease within the first few years of exposure
and the others at a later point in their lives. However, we are
unable to find good explanations for why 90% of infected humans
never develop disease. More recently, Horsburgh and colleagues
evaluated data from the United States, and they found a low
overall number of cases developing within the first 5 years after
a positive TST (76). Overall, there were only 27 TB cases among
7742 persons tested, or 0.35% over 5 years. However, among the
106 HIV infected persons in that study, there were 12 cases, or
11.3% over 5 years. This represents the highest rate of reactivation
studies.
Although HIV infection has been associated with high rates
of reactivation of TB, the use of TNF-alpha inhibitor drugs has
also been associated with a large amount of disease reactivation.
Early reports were case series that did not include data on baseline
TSTs or IGRAs (77). In a report from France on 69 cases of
TB associated with the use of TNF-alpha inhibitors, there were
15 TB cases among the 38 persons (39.5%) with TSTs of 5mm
or more.
So if we accept TNF inhibition as the strongest inducer of
reactivation TB, even more so than HIV, why do we not see
more than 40% develop active TB disease, especially when nearly
all NHPs who are experimentally infected and then treated with
TNF-alpha inhibition reactivate (34)? We propose one explana-
tion is that some people are exposed to large droplet aerosols of
M. tuberculosis that deposit in their upper airway and induce an
immune response but do not cause infection. The traditional test
defining LTBI has been the TST, but it reflects delayed hypersen-
sitivity to the antigens of M. tuberculosis and is only a surrogate
for cell-mediated immunity (CMI). The more recently developed
IGRAs are probably a better reflection of CMI. However, in
the discussion to follow, we suggest that both delayed hyper-
sensitivity and CMI may be stimulated without a true infection
occurring.
Cough Aerosol Particle Size Distribution in
Health and Disease
Aerosols are suspensions of particles in air (65, 78).The most
important determinant of particle deposition within the respira-
tory tract is the mass median aerodynamic diameter (MMAD), or
the diameter of a particle if it behaved as a sphere (65, 78). For
simplicity, we will simply use the term “diameter.” Most aerosols
in nature contain a wide range of sizes, or they are “polydisperse.”
“Monodisperse aerosols” of a single diameter can generally only
be produced in the laboratory.
Cough Aerosols from Healthy Humans
Most attempts to study the aerosols generated from the human
respiratory tract have used healthy volunteers. In early studies,
investigators applied dyes to the oral cavity and then measured
the large droplets from the “mouth spray” on oiled slides held
a few inches from the mouth; the size of smaller droplets were
estimated by calculations from the larger ones. There was a wide
range of particles from 1 to 2000μ (79) In a more recent study,
aerosols from five healthy human volunteers that were mouth
breathing, nose breathing, coughing, and talking were measured
using an optical particle counter and an analytical transmis-
sion electron microscope (80). Coughing produced the largest
concentrations of droplets, but there was considerable variabil-
ity. Most recently, Zayas and colleagues used a laser diffrac-
tion system to study 45 healthy subjects and found that volun-
tary coughs generated particles from 0.1 to 900μ in size (81)
(Figure 6).
Cough Aerosols During Pulmonary Infections
While the above data from healthy humans provide valuable
insights into the particle sizes that can be emitted from the human
respiratory tract, healthy humans do not cough and do not pro-
duce sputum. These data did not inform the size of the particles
in which pathogens were emitted and transported. The classic
and elegant early studies by Flugge, Riley, Wells, Lurie, and others
determined that aerosols were generated from TB patients, but to
our knowledge the particle size distribution had never been mea-
sured directly. The CASS apparatus discussed above is a method
of quantifying and sizing cough aerosols (63), and we found
that nearly all (96.4%) particles with culturable M. tuberculosis
in cough aerosols from patients with active pulmonary TB were
<4.7μ (67). In a study of patients with CF who were infected with
P. aeruginosa, we found that 72% of the cough aerosol particles
containing culturable P. aeruginosa were 3.3μ or less (60), with
a distribution similar to that of TB patients (Figure 7). However,
we also found culturable bacilli in the connector tubing between
the patient’s mouth and the sampling chamber (60), suggesting
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FIGURE 6 |Wide range of particle size distributions of aerosols
produced by voluntary coughing by healthy subjects. From Ref. (80).
carriage of bacilli in large droplets. In a follow-up study of 19 CF
patients at the same center, they all produced culturable aerosols
that were again markedly variable among the subjects and mostly
in particles <3.3μ. In addition, culturable P. aeruginosa was
isolated at 4 meters and persisted in the air for 45min (71).
Cough aerosols from patients with influenza have been
measured more recently. In one study using Andersen cascade
impactors as used for our TB and CF studies about, up to 89%
of particles one foot away from patients were <4.7μ (11% were
larger) (82). In another study using different sampling methods
of cough aerosols, influenza was found in 42% of particles <1
micron, in 23% of particles of 1–4μ, and in 35% of particles
FIGURE 7 | Particle size distributions of cough aerosols from patients
with active pulmonary TB [top panel; from Ref. (67)] and from cystic
fibrosis patients with chronic P. aeruginosa infections [bottom panel;
from Ref. (60)].
>4μ (83). In all of these studies, the sampling methods for viable
pathogens are technically limited to the smaller size ranges, so
our knowledge of the concentration of viable pathogens in large
droplets is limited.
In summary, in both health and disease, humans generate
cough aerosols in a broad range of particle sizes. Most pathogens
are found in particles <4–5μ, so predictably deposit in the lower
respiratory tracts. However, pathogens, includingM. tuberculosis,
are also present in larger particles that probably deposit in the
upper airways.
Primary TB of the Upper Airway
Given the above discussion about the size distribution of cough
aerosols from patients with pulmonary TB, it should not be
surprising that M. tuberculosis can deposit in the upper air-
ways. Most nasal TB occurs in conjunction with pulmonary TB.
Primary nasal TB, by definition without co-existing pulmonary
infection, is rare, but there are multiple case reports (84–88).
Laryngeal TB almost always occurs in tandem with pulmonary
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TB, but primary TB of the larynx occurs, probably more rarely
than primary nasal TB (89–93).
Primary oral TB is also rare, although M. tuberculosis may
be cultured from the dental plaque and saliva of patients with
pulmonary TB (94). In a study of TB patients with periodontal
disease, 92% had M. tuberculosis isolated in the saliva and 68%
in the dental plaque. In this endemic setting in India, 12% of
periodontitis patients not diagnosed with TB also had M. tuber-
culosis isolated from the saliva (95). In an unusual outbreak, a
dentist with pulmonary TB had presumably coughed into the
mouths of the cases or contaminated them with M. tuberculosis
on his fingers, resulting in 13 cases of primary intraoral TB and
involvement of regional lymph nodes, 1 case of both intraoral
and pulmonary TB, and 1 case of erythema nodosum and pleural
effusion (96). In several of these case reports, clinicians have
suspected that nose-picking and smoking/alcohol use are risk
factors for primary nasal and laryngeal TB, respectively. In the
case of the outbreak of primary intraoral TB, dental manipulation
or tooth extractions could obviously damage the oral mucosa.
The suspected need for damaged mucosa is supported by a study
using organ cultures of human tissue inwhichM. tuberculosis only
adhered to extracellular matrix in areas of mucosal damage, but
not to ciliatedmucosa, intact extruded cells, basementmembrane,
or collagen fibers (97). We suspect that the rarity of primary TB of
the upper airway is explained by the requirement of both damaged
mucosa as well as deposition of large aerosol particles from a TB
patient.
Cervical Lymphadenitis
The cervical lymph nodes are the most common site of TB
lymphadenitis. Cervical lymphadenitis due to M. tuberculosis is
thought by some authors to be a “local manifestation of a systemic
disease,” presumably via lymphatic drainage from pulmonary
lymph nodes (98). However, it is also clear that cervical nodesmay
become involved due to tuberculous infection in the head or neck
(99). In a study of 100 cases of histologically confirmedTB cervical
lymphadenitis, the most common site of disease was in the poste-
rior triangle (51%), followed by the upper deep cervical (48%) and
submandibular nodes (100). The supraclavicular and lower deep
cervical nodes were involved in only 3 and 9%, respectively. These
data suggest that an unappreciated source of infection of upper
cervical lymph nodes is the upper airway. Cervical lymphadenitis
from non-tuberculous mycobacteria, most common in children,
is assumed to be due to a portal of infection in the oropharynx or
conjunctiva (101). We propose that the same is likely to be true
for M. tuberculosis if we accept that it is found in large aerosol
droplets.
Mucosal Immunization via the Upper
Airway
Patients who suffer from “hay fever” (allergic rhinitis) are all
too familiar with the immunological hypersensitivity response
after airborne particles of pollen (that are usually around 20μ
or larger, similar to large droplet aerosols) deposit in the nose.
The mucosa of the upper airway is a rich connection between
the environment and the immune system. There is a rapidly
growing literature on the use of intranasal vaccination, also known
as mucosal immunization. Intranasal administration of vaccines
provides protection against a variety of respiratory pathogens
(102). Intranasal vaccinationwithM. bovisBCG can elicit not only
protection against aerosol challenge with M. tuberculosis H37Rv,
but it can also elicit granuloma formation in the deep lung (103).
Even heat-killed BCG delivered intranasally with an adjuvant can
induce systemic immune responses (104). Intranasal administra-
tion of BCG to mice appears to offer short-term protection in
the lung but persistent immune responses in the spleen for at
least 10months (105). We speculate that this may help explain
the poor ability of BCG vaccination to protect humans from pul-
monary TB but the documented protection against disseminated
disease.
Summary
An inoculum effect is common in most infectious diseases, and
we have reviewed data demonstrating the greater likelihood of
more progressive TB disease with greater magnitudes of inhaled
infectious aerosol or with surrogate measures for the same. We
propose that cough aerosols of M. tuberculosis are the best sur-
rogate measure to test our first hypothesis that inhaled dose
predicts immunopathology in human TB. Our second hypothesis,
that large droplet aerosols of M. tuberculosis can induce immune
responses without establishing infection can be tested in both
experimental animal models and perhaps in the near future in
humans with attenuated live mycobacteria or with mycobacterial
antigens. Such researchwould have the potential to discover better
biomarkers of true persisting infection, and hopefully, to better
identify those at risk for progression to active TB.
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